Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression Authors: He Tian, Jing Song, Junzi Cong, Zhihui Zhang, Yancheng Di, Benchun Yan, Xihao Nan Published: 2025 ABSTRACT AbstractBackgroundBladder cancer, a widely occurring malignant tumor worldwide, is closely related to the abnormal activation of numerous signaling pathways during its initiation, progression, and metastasis. Protein kinase D2 (PRKD2), as a member of the protein kinase D family, exerts a pivotal influence on human cancers. This research aimed to elucidate the involvement and mechanism of PRKD2 in bladder cancer.MethodsPRKD2 expression was analyzed using quantitative real-time PCR, Western blotting and tissue microarray (n = 30). Functional experiments were conducted to evaluate the biological phenotypes of cells, including CCK-8 assay, colony formation assay, flow cytometry analysis, scratch wound healing assay, Transwell migration assay, and mouse xenograft model. The phosphorylation of MCM2 by PRKD2 was examined using site-directed mutagenesis and immunoprecipitation assay assays.ResultsOur results revealed markedly elevated expression levels of PRKD2 in bladder cancer compared to control tissues. Increased PRKD2 expression was associated with lymph node metastasis, distant metastasis, advanced TNM staging, and poorer prognosis. Functional experiments demonstrated that depletion of PRKD2 impeded the proliferation, migration, invasion, and epithelial-mesenchymal transition of bladder cancer cells in vitro and in vivo. Mechanistically, PRKD2 phosphorylates complex component 2 (MCM2) at serine 139. This phosphorylation drives the malignant progression of bladder cancer cells.ConclusionsThese findings offer new insights into regulatory mechanisms involving PRKD2 contributing to the malignancy of bladder cancer, thereby presenting a potential therapeutic target.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-025-07067-0.Keywords: Protein kinase D2, Bladder cancer, Phosphorylation, Maintenance complex component 2 Background Bladder cancer ranks as one of the most prevalent cancer types worldwide, with an estimated 550,000 new cases and 170,000 deaths reported each year [1]. About 75% of patients are initially diagnosed with non-muscle invasive bladder cancer (NMIBC). However, up to 30% of NMIBC patients may eventually progress to muscle-invasive bladder cancer (MIBC) [2]. Transurethral resection is the cornerstone treatment for non-muscle-invasive bladder cancer and intravesical therapy can further improve oncological outcomes. For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the standard of care with evidence supporting trimodality therapy. Despite achieving objective remission following standard treatment in about half or more MIBC patients; resistance develops in half leading to an unfavorable prognosis. Although a substantial number of patients with MIBC achieve objective remission following standard treatment, resistance to therapies frequently develops, leading to an unfavorable prognosis for approximately half of these patients [3]. The intricate processes of tumor initiation, progression, and metastasis are closely associated with dysregulated cellular behaviors, including abnormal uncontrolled proliferation, migration, and invasion. These aberrations are often mediated by specific kinase signaling pathways, highlighting the critical importance of elucidating the roles of key kinase molecules in the context of bladder cancer [4, 5]. Therefore, identifying pivotal kinases involved in bladder cancer pathogenesis may uncover new and promising therapeutic targets. The Protein kinase D2 (PRKD2) protein, a member of the protein kinase D (PRKD) family, functions as an effector in diacylglycerol-regulated signal transduction pathways. PRKD family members can be activated through protein kinase C (PKC)-dependent or independent pathways [6]. Beyond their role as effectors in these pathways, PRKDs are implicated in numerous essential cellular processes such as DNA synthesis, gene expression, chromatin organization, and cell survival and differentiation [7–9]. Emerging evidence has highlighted the oncogenic potential of PRKD2 in various malignancies, including gastrointestinal cancers, triple-negative breast cancer, and gliomas [9–11]. For example, PRKD2 has been found to promote the expression of matrix metalloproteinases (MMPs), facilitating enhanced motility, invasion, and angiogenesis in pancreatic cancer cells [12]. Additionally, PRKD2 has been shown to regulate the cell cycle by promoting the G2-M transition through the stabilization of Aurora A kinase, where its depletion results in delayed mitotic entry and subsequent cell death [13]. However, the precise role and underlying mechanisms of PRKD2 in bladder cancer remain to be fully understood. Minichromosome maintenance protein 2 (MCM2) is a component of the prereplicative complex. It is essential for eukaryotic DNA replication and is only expressed in proliferating cells. The overexpression of MCMs was detected in various cancers, such as breast cancer, hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC), suggesting their role in cancer development and diagnosis. These findings indicate that MCM2 may be not only a diagnostic or prognostic marker but also a potential therapeutic target in multiple cancers. In this study, we examined the expression patterns of PRKD2 in bladder cancer and evaluated its association with clinicopathological factors and prognosis. We further explored the functional consequences of PRKD2 knockdown on the malignant biological properties of bladder cancer cells. Subsequently, Utilizing phosphoproteomics, we identified MCM2 as the target protein of PRKD2 and validated their regulation mechanism. The rescue experiments clarified the role of MCM2 phosphorylation in PRKD2-mediated carcinogenic activity. Finally, we assessed the therapeutic potential of targeting PRKD2/MCM2 in bladder cancer in vivo xenograft models. This research not only provides insights into the molecular mechanisms driving bladder cancer progression but also highlights the therapeutic relevance of PRKD2 and MCM2 as potential targets for clinical intervention. Method and materials Tissue specimens The specimens of 30 pairs of bladder cancer specimens and their adjacent normal tissues (ANTs) were collected from Hongqi Hospital between 2022 and 2024. This study was approved by the Medical Ethics Committee of Hongqi Hospital (approval no.2019040). Informed consent was obtained from all participants and all the protocols were conducted following the Helsinki Declaration. Western blot Proteins was isolated using RIPA lysis buffer (Beyotime, China). BCA protein assay kit (Vazyme Biotech Co., Ltd) was used for protein concentration measurement. 10 uL of protein samples underwent SDS-denatured 10% polyacrylamide gel electrophoresis (PAGE). For membrane transfer, the gel and PVDF membrane were placed in a sandwich clip at 4 °C with a constant flow of 200 mA for 1 h in the transfer buffer. The membrane was then incubated in the sealing liquid for 30 min at room temperature. Following this, the membrane was sectioned according to the position of protein blotting and immersed in the antibody dilution containing the corresponding primary antibody overnight at 4 °C. After rinsing with shaking in 1 × TBST solution, the membranes were placed in TBST containing the corresponding secondary antibody (HRP labeled sheep anti-Rabbit/mouse IgG antibody) at room temperature for 1 h. After rinsing by shaking in 1 × TBST solution, the membranes were placed in Super ECL Plus hypersensitive luminescent solution for 2 min, and then immediately placed in the exposure box for exposure. PRKD2 (Rabbit, 1:1000), E-cadherin (Rabbit, 1:5000), N-cadherin (Rabbit, 1:5000), Vimentin (Rabbit, 1:5000), and GAPDH (Mouse, 1:5000) antibodies were purchased from Proteintech (Wuhan, China). MCM2, MCM2-pS139, LNA-pS2152, and BRAF-pT401 antibodies were obtained from Abcam. Tissue microarray A tissue microarray (TMA) containing 30 pairs of bladder cancer specimens and their ANTs was obtained from Outdo Biotech, Ltd. (Cat No. HBlaU060CS02, Shanghai, China). The scoring methodology for tissue microarrays has been expanded to detail that two independent pathologists blinded to clinical data evaluated samples using H-scoring (calculated as: [3 × %strong staining + 2 × %moderate + 1 × %weak], range 0–300). Inter-rater reliability was confirmed with Cohen’s κ > 0.8. Cell culture Human ureteral epithelial immortalized cells SV-HUC-1 and human bladder cancer cell lines including 5637, 253J, T24, J82, and RT4, were purchased from Procell (Wuhan, China). SV-HUC-1 cells were cultured in Ham’s F-12K medium. 5637, 253J, and J82 cells were cultured in RPMI-1640 medium. T24 and RT4 cells were cultured in McCoy’s 5A medium and J82 cells in MEM medium. All media were supplemented with 10% fetal bovine serum (ThermoFisher, USA) and 1% Penicillin–Streptomycin solution, provided by Procell (Wuhan, China). Construction of plasmids, small interfering RNAs (siRNAs) and transfection The lentiviral PRKD2 short hairpin RNA (shRNA) and negative control (NC) were supplied by GeneChem (Shanghai, China). Cells were infected with lentivirus particles at a multiplicity of infection of 40 for 48 h. Stable cell lines were obtained via selection with puromycin (Solarbio, Beijing, China). MCM2 siRNAs and their negative control, and Flag-tagged MCM2 WT (NM_004526.4 CDS region), S139A (NM_004526.4 CDS region, amino acid S at position 139 is mutated to A), and S139E (NM_004526.4 CDS region, amino acid S at position 139 is mutated to E) overexpressed plasmids were purchased from General Biol (Anhui, China). These plasmid and siRNAs were transfected into bladder cancer cells using Lipo 3000 (L3000015, ThermoFisher, USA). The siRNA sequences of PRKD2 and MCM2 siRNA are listed in Table 1. Table 1The primer sequences used in this studyGENESPrimer sequencesPRKD2Forward: 5’ GCAAGTTTAACTGTCACAAACGC 3’Reverse: 5’ CTCCATCGGCACATCTCCAT 3’GAPDHForward: 5’ ATGACATCAAGAAGGTGGTGAAGCAGG 3’Reverse: 5’ GCGTCAAAGGTGGAGGAGTGGGT 3’MCM2 siRNAsNegative Control: 5′-GUUAUCGCAACGUGUCACGUA-3′MCM2 siRNA#1: 5′-CTGTCATCCTAGCCAACCA-3′MCM2 siRNA#2: 5′-GTCGCAGTTTCTCAAGTAT-3′MCM2 siRNA#3: 5′-CAGAGCAGGTGACATATCA-3′ The primer sequences used in this study Forward: 5’ GCAAGTTTAACTGTCACAAACGC 3’ Reverse: 5’ CTCCATCGGCACATCTCCAT 3’ Forward: 5’ ATGACATCAAGAAGGTGGTGAAGCAGG 3’ Reverse: 5’ GCGTCAAAGGTGGAGGAGTGGGT 3’ Negative Control: 5′-GUUAUCGCAACGUGUCACGUA-3′ MCM2 siRNA#1: 5′-CTGTCATCCTAGCCAACCA-3′ MCM2 siRNA#2: 5′-GTCGCAGTTTCTCAAGTAT-3′ MCM2 siRNA#3: 5′-CAGAGCAGGTGACATATCA-3′ CCK-8 assay 5 × 103 cells were inoculated into a 96-well plate. At 0 h, 24 h, 48 h, and 72 h, 10 ul CCK8 solution was added to each well and incubated for 4 h. The absorbance of each well at 450 nm was measured by enzymoleter. Colony formation assay Cells (500 cells/well) were seeded into each well of a 6-well plate, and cultured under optimal conditions for 12–15 days until visible colonies formed. The colonies were then washed twice with PBS buffer and fixed with 4% paraformaldehyde for 15 min. Following washing, they were stained with 0.4% crystal violet solution for 15 min. After washing and drying, the cell colonies were counted and imaged under an optical microscope. The colony formation efficiency was calculated using the formula: (number of colonies formed / total number of initially seeded cells) × 100%. Cell cycle analysis The cells were harvested and resuspended in 1 mL of pre-chilled PBS. Subsequently, 4 mL of pre-chilled 95% ethanol was added dropwise to the cell suspension while gently vortexing at low speed (on ice), followed by fixation at 4 °C for 12–24 h. Finally, each tube received an addition of 0.4 ml propidium iodide solution and incubated at 37 °C for 30 min. The samples were analyzed using flow cytometry (Beckman, USA). Wound healing When the cells reached confluence, a straight line was delineated along the central axis of the well using 10 μL micro-sampling tips. Subsequently, after removing the floating cells with PBS, the cells were cultured in a complete medium for 0 h, 24 h, and 48 h respectively. The observation and photography of cell migration were conducted under a light microscope. The migration rate at N hours (%) was calculated using the formula: (scratch area at 0 h—scratch area at Nh)/scratch area at 0 h × 100% Transwell invasion assay 1 × 105 cells in 100 µL serum-free medium were seeded onto the upper layer of the Transwell chamber pre-treated with Matrigel, while 600 µL of complete medium was added to the lower compartment of the Transwell chamber. The cells were then incubated for a duration of 48 h. Following removal of the upper layer cells, those in the lower compartment were treated with 4% pre-chilled paraformaldehyde for 30 min and subsequently stained with Giemsa dye for a period of 15 min. The resulting cellular morphology was observed and documented using light microscopy. Immunofluorescence staining Cells were treated with 4% paraformaldehyde solution for 15 min, followed by a fixation reaction with 0.1 M glycine. The cells were subsequently sealed with 100 µL of sealing liquid for 40 min and incubated with diluted monoclonal antibodies in PBS-TX at room temperature for 4 h. After washing with PBS-TX, cells were exposed to a diluted secondary antibody and incubated for 2 h in darkness. Next, DAPI solution (100 µL) was applied for nuclear staining. After another round of washing with PBS-TX, a drop of anti-fluorescence quenching sealing solution (4 µL) was added to the slide. Images were obtained with a Carl Zeiss Axioskop 2 plus (Carl Zeiss, 63 × /1.40 Oil DIC) microscope using ZEN software (Carl Zeiss) and processed using ZEN software (Carl Zeiss). Analysis of protein phosphorylation analysis PRKD2-knockdown 253J cells and their corresponding negative controls were utilized for proteomic and phosphoproteomic analysis via LC–MS/MS (Thermo Fisher, Orbitrap Eclipse Tribrid). Initially, peak identification was performed on the raw MS data to generate the peak list (Q ExactiveHF). Subsequently, phosphorylated peptides and proteins were identified through database searching (UniProt). The differentially expressed phosphorylated proteins (∣Fold Change∣ > 2, p < 0.05) were characterized and subjected to gene ontology (GO) functional annotation, as well as KEGG enrichment analysis. Additionally, protein interaction analysis was conducted for the differentially expressed phosphorylated proteins. FDR thresholds: 1% at PSM, peptide, and protein levels. Each biological sample was enriched three times. Immunoprecipitation (IP) assay The cells were treated with RIPA lysis buffer containing PMSF and NaF on ice for 10 min. Following centrifugation at 14,000 g for 10 min, the supernatant of the cell lysate was collected and kept on ice. The diluted antibody (PRKD2 or Flag antibody) was combined with pre-treated magnetic beads and incubated on a rotating wheel (room temperature, 30 min; 4 °C, 2 h). Subsequently, the antibody-magnetic bead complex was mixed with the prepared cell lysate sample and incubated on a rotating wheel (room temperature, 30 min; 4 °C, 2 h) to facilitate antigen binding. The magnetic beads were then mixed with 1 × SDS-PAGE loading buffer and heated at 95 °C for 5 min. The resulting supernatant was used for protein detection of PRKD2 and MCM2 pS139 or Flag-MCM2 by western blot. Mouse xenograft experiments The 253J and T24 cells were infected with lentiviruses carrying NC, si-PRKD2 + empty vector, or si-PRKD2+MCM2-S139E, and stable transfectants were constructed. Thirty-six 5-week-old male BALB/c-nu nude mice were adaptively raised for one week and then randomly divided into six groups, with six mice per group. Each group received subcutaneous injections of the constructed 253J or T24 cells. The mice were then maintained in an SPF-level environment with a 12-h light/dark cycle for 28 days. Tumor size was measured weekly to plot growth curves. At the end of the experiment, the mice were euthanized, and tumors were excised for Western blot and immunohistochemistry analysis. The animal experiments were performed following ARRIVE guidelines and approved by the Medical Ethics Committee of Hongqi Hospital (No.2019040). RT-qPCR analysis Total RNA was extracted from cells and tissues with TRIzol™ Reagent (Invitrogen). cDNA synthesis employed the PrimeScript™ RT Kit (Takara) per manufacturer’s instructions. Quantitative PCR was performed using SYBR™ Premix Ex Taq™ II (Takara) on a StepOnePlus™ System (Applied Biosystems), with GAPDH as endogenous control. Relative gene expression was calculated via the 2(-ΔΔCt) method. Immunohistochemistry (IHC) staining Formaldehyde-fixed, paraffin-embedded tissue sections were used for IHC experiment. Tissue sections were deparaffinized, and antigen retrieval was performed in 10 mM citric buffer, pH6.0 at 100 °C for 10 min. Endogenous peroxidase activity was quenched with 3% H2O2, and serum was used to block non-specific binding sites with the Endogenous Biotin-Blocking Kit (Thermo Fisher Scientific, USA). Then, the slides were stained with anti-HIPPI monoclonal primary antibody (1:50, Mouse, Thermo Fisher Scientific, USA) at 4 °C for 22 h, washed and then incubated with a biotinylated anti-rabbit lgG secondary antibody for 30 min at room temperature. Slides were counterstained with hematoxylin. The representative photographs were taken using Olympus BX50 microscope (Japan). Slides were evaluated using light microscopy and a standard semi-quantitative immunoreactivity score as described previously. Statistical analysis Statistical analysis was performed using GraphPad Prism 8.0. The cell experimental data were presented as the mean ± standard deviation (SD) from at least three independent experiments. Differences between the two groups were assessed using Student’s t-test, while survival analysis utilized Kaplan–Meier curves. Kaplan–Meier curves were compared using log-rank tests with Bonferroni adjustment for multiple groups. One-way or two-way ANOVA was employed for comparisons involving more than two groups. A significant level of P < 0.05 was considered statistically significant. Results Expression and clinical significance of PRKD2 in bladder cancer We measured PRKD2 expression in the bladder cancer tissues and ANTs from 30 patients using qRT-PCR. The results demonstrated higher PRKD2 mRNA levels in cancerous tissues compared to ANTs (Fig. 1A). Furthermore, higher expression of PRKD2 was correlated positively with lymph node metastasis (P = 0.018), distant metastasis (P = 0.002), and TNM staging (P = 0.005), as outlined in Table 1. Next, 30 bladder cancer patients were divided into high PRKD2 expression group (n = 15) and low PRKD2 expression group (n = 15). Kaplan–Meier plotter demonstrated that high PRKD2 expression was predictive of poorer prognosis (Fig. 1B). Western blot analysis further confirmed that PRKD2 protein levels were higher in bladder cancer tissues than in ANTs (Fig. 1C). Moreover, immunohistochemical staining of a TMA containing 30 pairs of human bladder cancer and normal tissues demonstrated heightened positive staining for PRKD2 in bladder cancer tissues, with a higher H-score in bladder cancer tissues as calculated by Quant Center software (Fig. 1D). Collectively, these results strongly suggest that elevated levels of PRKD2 are significantly linked to bladder cancer progression. PRKD2 expression is upregulated in bladder cancer and correlates with prognosis. A Analysis for PRKD2 mRNA levels in 30 paired samples of bladder cancer. B Kaplan–Meier survival analysis comparing patients with high PRKD2 expression and those with low PRKD2 expression. C Western Blot analysis for PRKD2 protein expression paired samples of bladder cancer. D Immunohistochemical staining for PRKD2 protein on a tissue microarray containing 30 paired bladder cancer tissues and ANTs. ANTs adjacent normal tissues. **P < 0.01, ***P < 0.001 Knockdown of PRKD2 inhibits cell proliferation, migration, and invasion in bladder cancer cells We measured PRKD2 expressions in the human uroepithelial cell line SV-HUC-1 and bladder cancer cell lines, including 5637, 253J, T24, J82, and RT4 cells. Western blot results showed that PRKD2 protein levels were significantly upregulated in bladder cancer cell lines compared to SV-HUC-1 cells (Fig. 2A). Subsequently, we employed shRNAs to knock down PRKD2 in T24 and 253J cells. CCK-8 and colony formation assays showed that silencing of PRKD2 suppressed the proliferation and colony-formation ability in T24 and 253J cells (Fig. 2B, C). PRKD2 knockdown significantly decreased the EdU-positive rate (Fig. 2D). Additionally, we analyzed the impact of PRKD2 knockdown on cell cycle progression, observing an increase in G1 phase accumulation and a decline in G2 phase cells in PRKD2-depleted cells (Fig. 2E), suggesting that PRKD2 depletion leads to G0/G1 phase arrest. Knockdown of PRKD2 inhibits malignant biological characteristics in bladder cancer cells. A Western blot analysis of PRKD2 protein levels in SV-HUC-1 and bladder cancer cells. *P < 0.05, **P < 0.01, ***P < 0.001 vs the SV-HUC-1 group. B–D The proliferative potential of T24 and 253J cells was evaluated using CCK8 (B), colony formation (C), and EDU (D) assays following transfected with negative control (NC) and sh-PRKD2. The bar in (D) indicates 100 μm. E Cell cycle distribution of T24 and 253J cells analyzed by FCM following treatment with NC and sh-PRKD2. F Migration potential was assessed by Wound healing assays following exposure to NC and sh-PRKD2 transfection. G Invasion ability of T24 and 253J cells evaluated by Transwell invasion assays following exposure to NC and sh-PRKD2 transfection. H Western blot analysis and I IF staining were conducted to quantify the protein levels of E-cadherin, N-cadherin, and Vimentin in T24 and 253J cells following exposure to NC and sh-PRKD2 transfection. The bar in (I) indicates 50 μm. *P < 0.05, **P < 0.01, ***P < 0.001 We then assessed the influence of PRKD2 on the migratory and invasive potential of bladder cancer cells. Wound healing assays showed significantly reduced wound closure in PRKD2-knockdown cultures of T24 and 253J cells (Fig. 2F). Similarly, transwell invasion assay demonstrated a marked reduction in the invasive capabilities of these cells following PRKD2 downregulation (Fig. 2G). Furthermore, decreased expression of PRKD2 resulted in significant alterations in epithelial and mesenchymal markers in bladder cancer cells, including elevated E-cadherin levels and reduced N-cadherin and Vimentin levels as demonstrated through Western blot analysis (Fig. 2H) and confirmed by immunofluorescence assays (Fig. 2I). These findings collectively suggest that PRKD2 inhibition significantly suppresses the migration and invasion of bladder cancer cells. MCM2 is identified as a potential downstream target of PRKD2 Previous reports have shown that PRKD2 acts as a serine/threonine kinase, involved in the phosphorylation of proteins, such as DSG2 and AKT [14, 15]. To investigate the potential downstream targets of PRKD2, quantitative phosphoproteomics analysis was conducted to identify phosphoproteome changes in 253J cells following PRKD2 knockdown. A total of 1401 unique phosphopeptides mapping to 1401 phosphoproteins exhibited significant differences (ratio change > 2.0 in either direction and P-value < 0.05) between NC and PRKD2-KD groups, including, 607 upregulated and 794 downregulated phosphopeptides in PRKD2-KD 253J cells (Fig. 3A). The differentially expressed phosphoproteins were primarily localized in the intracellular part and nucleus, were involved in regulating the biological regulation, macromolecule metabolic process, and exhibit protein-binding and nucleic acid characteristics (Fig. 3B). KEGG pathway enrichment analysis demonstrated that these phosphoproteins were notably clustered in cell cycle, regulation of actin cytoskeleton, and insulin signaling pathway (Fig. 3C). Notable cancer-associated phosphoproteins, including pS139-MCM2, pS2152-FLNA, and pT401-BRAF, exhibited significant differential expression (Fig. 3D) and were selected for further study. Subsequent Western blot analysis confirmed that PRKD2 knockdown notably reduced pS139-MCM2 levels in both T24 and 253J cells, with a mild effect on pS2152-FLNA and pT401-BRAF levels (Fig. 3E). Additionally, immunofluorescence staining illustrated a marked decrease in MCM2-pS139 fluorescence intensity in PRKD2-deficient cells compared to the NC (Fig. 3F). In addition, Western blot analysis revealed a significant increase in pS139-MCM2 levels in bladder cancer tissues compared to ANTs (Fig. 3G). These results indicate that MCM2 is a potential downstream target of PRKD2. MCM2 is identified as a potential target of PRKD2. A 253J cells were treated with sh-PRKD2 and NC, and subjected to quantitative phosphoproteome using mass spectrometry. Bar graph showing the number of upregulated and downregulated differentially expressed phosphosites. B GO functional annotation of DEPs. C Analysis of KEGG pathway enrichment of DEPs. D Phosphopeptides of MCM2-pS139, FLNA-pS2152, and BRAF-pT401 were identified. E Western blot analysis for pS139-MCM2, pS2152-FLNA, and pT401-BRAF protein levels in T24 and 253J cells following treatment with NC and sh-PRKD2. F Immunofluorescence staining of MCM2-pS139 in T24 and 253J cells following treatment with NC and sh-PRKD2. G Western blot analysis for pS139-MCM2 in 30 paired samples of bladder cancer. **P < 0.01 PRKD2 directly phosphorylates MCM2 at Ser139 To further investigate the interaction between PRKD2 and MCM2, co-IP assays utilizing an anti-PRKD2 antibody demonstrated the binding of pS139-MCM2 to PRKD2 in both T24 and 253J cells (Fig. 4A). Furthermore, the alignment of MCM2 across different species revealed that Ser 139 are highly conserved in many vertebrate species (Fig. 4B left), suggesting their functional importance. To confirm that the interaction was mediated through the S139 site of MCM2, we generated phospho-deficient mutants for MCM2 (S139A, serine at position 139 is replaced by alanine to simulate non-phosphorylation), phospho-mimetic mutants of MCM2 (S139E, serine at position 139 is replaced by glutamic acid to mimic phosphorylation) and wild-type (WT) Flag-tagged plasmids (Fig. 4B right). Immunofluorescence staining indicated successful transfection of these Flag-tagged plasmids into T24 and 253J cells (Fig. 4C). Furthermore, MCM2 expression was knocked down using siRNA in T24 and 253J cells, and Western blot analysis confirmed that siRNA targeting MCM2#2 had the most pronounced inhibitory effect on MCM2 levels (Fig. 4D), leading to its selection for further experiments. We then introduced WT and mutant plasmids of MCM2 (S139A and S139E) into the MCM2-silenced cells. As shown in Fig. 4E, both WT and mutant plasmids successfully increased the total MCM2 and Flag protein expression. Co-IP experiments using an anti-Flag antibody indicated that both MCM2-WT and MCM2-S139E interacted with PRKD2, while when S139 was mutated to A, MCM2 lost its ability to interact with PRKD2 (Fig. 4F). Furthermore, Co-IP using an anti-PRKD2 antibody reinforced the notion that PRKD2 interacts with MCM2 through the S139 domain (Fig. 4G). These findings confirm that PRKD2 directly phosphorylates MCM2 at the Ser139 residue. PRKD2 directly phosphorylates MCM2 at Ser139. A Co-immunoprecipitation of PRKD2 and pS139-MCM2 in 253 J and T24. Endogenous pS139-MCM2 was immunoprecipitated by anti-PRKD2 antibody. IgG, immunoglobulin G. B A primary structure of MCM2 and sequence alignment of conserved S139 across human, mouse, rat, and cow (left). Schematic presentation of the MCM2 S139 site and its mutants S139A and S139E (right). C An immunoprecipitation (IP) assay using an anti-Flag antibody was performed to detect the Flag-tagged MCM2 and mutants. D Western blot analysis of MCM2 in T24 and 253J cells transfected with MCM2 siRNAs. E Western blot analysis of MCM2, pS139-MCM2, and Flag in MCM2-knockdown T24 and 253J cells co-transfected with MCM29-WT, MCM2-S139A or MCM2-S139E. F IB analysis of Flag-IP products and WCL derived from PRKD2-knockdown T24 and 253J cells transfected with indicated Flag-MCM2 WT and SA/SE mutants (G) IB analysis of PRKD2-IP products and WCL derived from PRKD2-knockdown T24 and 253J cells transfected with indicated Flag-MCM2 WT and SA/SE mutants. SA, MCM2-S139A mutant; SE, MCM2-S139E mutant; EV, Empty vector control PRKD2-mediated MCM2 phosphorylation promotes oncogenic functions in bladder cancer cells To investigate the biological implications of PRKD2-mediated MCM2 phosphorylation, we reintroduced WT and variants of MCM2 (S139E and S139A) into PRKD2-deficient T24 and 253J cells. We noted that the absence of PRKD2 led to decreased levels of MCM2-pS139. Interestingly, introducing either MCM2-WT or MCM2-S139E significantly restored the expression of pS139-MCM2 in PRKD2-deficient cells, whereas the MCM2-S139A variant did not influence pS139-MCM2 expression (Fig. 5A). Furthermore, PRKD2 knockdown hindered cell colony formation of T24 and 253J cells. However, the reintroduction of MCM2-WT or MCM2-S139E markedly enhanced colony formation capabilities in these cells, while MCM2-S139A did not bring about any improvement (Fig. 5B). In terms of cell behavior, silencing PRKD2 disrupted migration and invasion in the T24 and 253 J cell lines. Nonetheless, the presence of MCM2-WT and MCM2-S139E restored these migratory and invasive capacities in PRKD2-deficient cells, whereas MCM2-S139A had no effect (Fig. 5C, D). Additionally, the absence of PRKD2 inhibited the EMT, as indicated by lower levels of E-cadherin and higher levels of N-cadherin and Vimentin. Reintroducing MCM2-WT and MCM2-S139E partially counteracted these changes, while MCM2-S139A did not affect the EMT indicators (Fig. 5E). Notably, in PRKD2-knockdown cells, we observed elevated fluorescence for E-cadherin and diminished fluorescence for N-cadherin compared to control cells. This pattern was reversed by the reintroduction of MCM2-WT and MCM2-S139E, while MCM2-S139A showed no significant impact (Fig. 5F). Collectively, these findings indicate that PRKD2-mediated MCM2-phosphorylation facilitates oncogenic functions in bladder cancer cells. PRKD2-mediated MCM2 phosphorylation promotes oncogenic activity. A Western blot analysis was performed to evaluate pS139-MCM2 levels in PRKD2-knockdown cells treated with the specified constructs. B Colony formation assay, C wound healing, and D Transwell assays were conducted in PRKD2-knockdown cells treated with the specified constructs. D Western blot analysis of MCM2-S139 in PRKD2-knockdown cells co-transfected with the indicated constructs. E Western blot analysis of E-cadherin, N-cadherin, and Vimentin in PRKD2-knockdown cells co-transfected with the indicated constructs. F immunofluorescent staining of E-cadherin and N-cadherin in PRKD2-knockdown cells co-transfected with the indicated constructs. *P < 0.05, **P < 0.01, ***P < 0.001 vs the NC groups. #P < 0.05, ##P < 0.01, ###P < 0.001 vs the PRKD2-KD + EV groups PRKD2 deficiency suppresses tumor growth and ETM in vivo We established subcutaneous xenograft models using modified bladder cancer cells in BALB/c nude mice (Fig. 6A). As shown in Fig. 6B and C, the absence of PRKD2 notably inhibited tumor growth and tumor weight, but this effect could be reversed with the addition of MCM2-pS139E. Moreover, Western blot analysis showed that PRKD2 knockdown led to reduced expressions of pS139-MCM2, and N-cadherin, and increased E-cadherin expression. Conversely, MCM2-pS139E administration counteracted these expression changes; However, the addition of MCM2 pS139E did not affect PRKD2 expression (Fig. 6D). Furthermore, immunohistochemical staining further indicated that PRKD2 deficiency resulted in decreased pS139-MCM2, N-cadherin and Ki-67 expression and increased E-cadherin expression in tumor tissues; however, these effects were reversed upon MCM2 pS139E administration (Fig. 6E). Altogether, these results imply that PRKD2 enhances tumor growth and EMT processes in bladder cancer, likely through the phosphorylation of MCM2. PRKD2 deficiency inhibits tumor formation and promotes EMT in xenograft tumors. Stably transfected T24 and 253J cells were generated using lentiviruses carrying the vector (WT), shPRKD2, or shPRKD2 + MCM2 S139E. These cells were subcutaneously injected into Balb/c nude mice (n = 6). A Images of xenograft tumors. B Tumor volume analysis. C Tumor weight measurement. D Western blot analysis of PRKD2, MCM2 pS139, E-cadherin, and N-cadherin in tumor tissues. E IHC staining for Ki67, E-cadherin, and N-cadherin in tumor tissues **P < 0.01, ***P < 0.001 vs the NC groups; #P < 0.05, ##P < 0.01, ###P < 0.001 vs the PRKD2-KD + EV groups Discussion PRKD2 has been identified as an oncogene contributing to the progression of various cancers, such as glioblastoma, gastric cancer, prostate cancer, and breast cancer [6, 16, 17]. Research indicates that PRKD2 is frequently overexpressed in pancreatic cancer, breast cancer, and gastrointestinal tumors [18]. This abnormal expression promotes malignant cell proliferation, migration, and invasion, implicating PRKD2 in tumor initiation and progression across diverse malignancies [19, 20]. Inhibition of PRKD2 has been demonstrated to suppress cancer cell proliferation and invasiveness while enhancing sensitivity to chemotherapy [21]. In line with these findings, our study revealed significantly elevated PRKD2 levels in bladder cancer. Elevated PRKD2 expression exhibited a significant correlation with lymph node metastasis, distant metastasis, advanced TNM staging, and less favorable patient outcomes. However, the maturity of current survival data limits the ability to draw definitive conclusions, and future studies should extend follow-up times to verify the results. These findings indicate that PRKD2 may function as a promising prognostic indicator in bladder cancer. Functional investigations confirmed that reducing PRKD2 levels inhibits cell proliferation, migration, and invasive potential in bladder cancer both in vitro and in vivo, thereby reinforcing the idea that PRKD2 functions as an oncogene in this context. As serine/threonine protein kinase, PRKD2 and its family members phosphorylate a variety of substrates, including significant oncogenes like beta-catenin[22], VEGF-A [18], Golgi phosphoprotein 3 [23]. For instance, Nickkholgh, et al. [24] demonstrated that PRKD1 directly phosphorylates cell division cycle proteins (Cdc25s), leading to cell cycle arrest in the G1 phase. Similarly. Zou et al. [25] showed that PRKD2 activates the p65 subunit of NF-κB by phosphorylating it at serine 276 in prostate cancer cells. In our research, we identified MCM2 as a likely target of PRKD2. Co-immunoprecipitation assays confirmed the direct interaction and phosphorylation of MCM2 by PRKD2, providing evidence for the regulatory relationship between these proteins. However, the phosphorylation was not further validated biochemically via in vitrokinase assays. We acknowledge this limitation and propose that future work should focus on reconstituting PRKD2-mediated MCM2-S139 phosphorylation in a cell-free system to establish definitive biochemical causality. MCM2 is a critical component of the MCM protein family, which plays an indispensable role in initiating DNA replication in proliferating cells. Phosphorylation is vital for regulating the activity and function of these MCMs. The phosphorylation of MCM2 is a sign of the beginning of the S phase and DNA synthesis [26]. Dysfunctional phosphorylation of MCM2 disrupts DNA replication and cell cycle progression, contributing to the development of various diseases, including cancers [27]. The work of Najar et al. [28] indicated that cyclin-dependent kinases promote the phosphorylation of MCM2 and MCM3, leading to the proliferation of gastric cancer cells. Additionally, Benzydamine has been shown to inhibit MCM2 phosphorylation, resulting in cell cycle arrest and growth inhibition in esophageal squamous cell carcinoma [29]. In our study, we elucidated the biological implications of MCM2 phosphorylation in the context of PRKD2 depletion.Restoration of MCM2-WT or the phospho-mimetic mutant MCM2-S139E in PRKD2-deficient cells reversed the inhibition of cell proliferation and invasiveness and corrected alterations in epithelial-mesenchymal transition (EMT) markers. However, the MCM2-S13A mutation did not affect the oncogenic activity induced by PRKD2. Subsequent studies could specifically inhibit kinase activity while preserving PRKD2 protein integrity to further refine the mechanistic framework of these findings, its structural function as a scaffolding protein versus its kinase-dependent phosphorylation regulatory mechanisms. Furthermore, in vivo experiments with xenograft models confirmed the ability of phosphorylated MCM2 (MCM2-pS139E) to reverse tumor growth suppression in PRKD2-deficient environments. These findings highlight that PRKD2-mediated phosphorylation of MCM2 is crucial for maintaining the aggressive phenotype characteristic of bladder cancer cells. Based on previous findings, MCM2 regulates CXCL1 in gliomas, Activate the MAPK pathway and maintain CSC characteristics and EMT. Therefore, further research can investigate how MCM2-pS139 promotes epithelial-mesenchymal transition and invasion by regulating CSCs. Based on a thorough exploration of the findings of this study, it is necessary for us to more specifically look forward to the translational prospects of targeting the PRKD2/MCM2-pS139 axis in bladder cancer treatment. Given that PRKD2 may act as a potential upstream kinase regulating the phosphorylation state of MCM2-pS139, developing highly selective PRKD2 kinase inhibitors or designing strategies to directly intervene at the MCM2-pS139 phosphorylation site theoretically provides new approaches to overcoming clinical challenges in bladder cancer. The core value of such targeted therapies lies in their potential to precisely interfere with the maintenance of stemness and invasive phenotypes of bladder cancer stem cells. Notably, the high expression or abnormal activation status of MCM2-pS139 itself may serve as a valuable biomarker for predicting patient responsiveness to specific targeted treatments or assessing the risk of invasion and recurrence, thereby enabling personalized treatment stratification and prognosis assessment. Ultimately, only through rigorous preclinical pharmacodynamics and safety evaluations can a solid foundation be laid for early clinical trials based on PRKD2/MCM2-pS139-targeted interventions, potentially opening up new avenues for improving bladder cancer treatment. Conclusion Our work elucidates the critical role of PRKD2 in bladder cancer, specifically highlighting its function as a mediator of MCM2 phosphorylation, which in turn drives oncogenic processes. These insights not only enhance our understanding of bladder cancer biology but also underscore the potential for targeting PRKD2 in therapeutic strategies aimed at improving patient outcomes. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Abbreviations Non-muscle invasive bladder cancer Muscle-invasive bladder cancer Protein kinase D2 Protein kinase C Matrix metalloproteinases Minichromosome maintenance protein 2 Adjacent normal tissues Polyacrylamide gel electrophoresis Tissue microarray Short hairpin RNA Negative control Gene ontology Standard deviation Author contributions HT, JS and HB XN. Conceived and designed the experiments. HT, JS, JC and ZZ performed the experiments. YD and BY conducted the statistical analyses. HT wrote the paper and XN revised the paper. All authors read and approved the final manuscript. Funding This study was granted by the the Foundation of HongQi: 2019HQ-01. Data availability The datasets generated and/or analyzed during the study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Medical Ethics Committee of Hongqi Hospital (No.2019040). All the clinical protocols were conducted following the Helsinki Declaration. The animal experiments were performed following ARRIVE guidelines. Consent for publication Informed consent was obtained from all participants. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analyzed during the study are available from the corresponding author upon reasonable request.